CurrentBlue Cross Blue Shield - MassachusettsPolicy 732

Chemical Peels (Dermatology)

Medical policy governing coverage and prior authorization for chemical peel procedures for commercial members, including indications considered medically necessary (eg, numerous actinic keratoses, active acne after failed therapy) and indications considered cosmetic or investigational.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyChemical Peels (Dermatology)

Policy CodePolicy 732

Change TypeNo material change

Effective Date

Next Review Date

Key ActionPrecertification/preauthorization is required for all products if the procedure is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3peel depth categories

40%-70%AHAs concentration

15788-15793covered CPT codes

17360not medically necessary CPT

Multiplepolicy review history

Medically Necessary and Not Medically Necessary Indications

Covered when ALL of the following are met

Dermal peels for actinic keratoses: Dermal chemical peels used to treat individuals with numerous (>10) actinic keratoses or other premalignant skin lesions, such that treatment of the individual lesions becomes impractical, may be considered MEDICALLY NECESSARY.>10 lesions

from policy statements

Epidermal peels for active acne: Epidermal chemical peels used to treat individuals with active acne that has failed a trial of topical and/or oral antibiotic acne therapy are considered MEDICALLY NECESSARY; in this setting, superficial chemical peels with 40% to 70% alpha hydroxy acids are used as a comedolytic therapy.failed topical and/or oral antibiotic therapy

alpha hydroxy acid concentration 40%-70% cited

Cosmetic/Investigational indications: Epidermal chemical peels used to treat photoaged skin, wrinkles, or acne scarring or dermal peels used to treat end-stage acne scarring are considered cosmetic and INVESTIGATIONAL (not medically necessary).

policy classifies these as cosmetic/investigational

Epidermal chemical peels performed to improve photoaged skin, reduce wrinkles, or treat acne scarring are classified by this policy as cosmetic and investigational and are not considered medically necessary. Similarly, dermal chemical peels performed specifically to treat end‑stage acne scarring are also considered cosmetic and investigational and excluded from medical necessity coverage.

The policy references the ASDS consensus guidance on procedural safety during and after isotretinoin therapy, noting specific safety considerations for lasers, dermabrasion, chemical peels, energy devices, and skin surgery. These guidance documents imply temporal precautions or exclusions for performing procedures around isotretinoin use and should be followed when scheduling and planning chemical peel procedures.

CPT code 17360 (chemical exfoliation for acne) is listed in the policy as not medically necessary. In keeping with the policy classification, procedures intended to treat photoaging, wrinkles, or acne scarring (epidermal peels) and end‑stage acne scarring (dermal peels) are considered cosmetic/investigational and are not eligible for coverage under this policy.

Provider Actions and Authorization

Prior Authorization

Prior Authorization Required

Prior Authorization — Precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient. Outpatient prior authorization is not required for Commercial Managed Care (HMO and POS), PPO, and Indemnity.

Inpatient procedures: precertification/preauthorization required for all products.
Outpatient procedures: prior authorization is not required for Commercial Managed Care (HMO and POS), Commercial PPO, and Indemnity.

Step Therapy

Therapy Sequencing for Acne

Therapy sequencing for acne: Epidermal chemical peels for active acne are considered medically necessary only after failure of topical and/or oral antibiotic acne therapy. Superficial chemical peels (40%–70% alpha hydroxy acids) are used as a comedolytic therapy in this setting.

Epidermal chemical peels for active acne are medically necessary after failure of topical and/or oral antibiotic therapy.
Typical agents: superficial peels with 40%–70% alpha hydroxy acids used as comedolytic therapy.

Documentation Required

Documentation and Coding Guidance

Documentation requirements: No specific documentation requirements are stated in the policy references. Providers should, however, report all services using the most up-to-date procedure, revenue, and diagnosis codes and include modifiers where applicable.

No additional documentation requirements are specified in the reference listings.
Providers should report services using current procedure, revenue, and diagnosis codes (including modifiers where applicable).

Definitions

Chemical peel — definition

DefinitionChemical peel: a controlled partial-thickness removal of the epidermis and outer dermis; regeneration produces a 2–3 mm band of dense, compact collagen between the epidermis and damaged dermis, reducing fine wrinkles and pigmentation.

MechanismRemoval of damaged epidermal/outer dermal layers followed by skin regeneration and collagen formation leading to clinical improvement in texture and pigmentation.

Potential complicationsLocal complications include scarring, infection, hypopigmentation, hyperpigmentation, activation of herpes simplex, and toxic shock syndrome.

Peel depth categories

Superficial (epidermal)Affects the epidermis and dermal–epidermal interface; indicated for mild photoaging, melasma, comedonal acne, and postinflammatory erythema; common agents include low‑concentration glycolic acid, Jessner solution, tretinoin, salicylic acid, and low‑concentration TCA (≈10%–20%); healing 1–4 days; multiple sessions (typically 6–8) performed weekly or biweekly.

Medium‑depth (dermal)Extends to the papillary dermis; used for more pronounced photodamage and premalignant lesions; commonly performed with 35% TCA combined with Jessner solution or 70% glycolic acid (phenol 88% also used historically); healing involves mild–moderate edema and re‑epithelialization; avoid repeat medium‑depth peels for at least 1 year.

Deep (mid‑reticular dermis)Penetrates to the mid‑reticular dermis; indicated for severe photodamage, premalignant neoplasms, acne scarring, and dyschromias; commonly uses Baker (phenol) solution; higher risk profile including cardiotoxicity, renal/hepatic toxicity, and long‑term pigmentary disturbances; prolonged sun protection required (9–12 months).

Actinic keratosis (AK) — references and treatment context

AK as a continuumReferences characterize actinic keratosis (AK) as a disease continuum with risk of progression to squamous cell carcinoma and discuss field‑directed approaches.

Evidence for peels in AKSystematic reviews and randomized trials evaluate chemical peels (eg, 35% TCA ± Jessner, phenol peels) for treatment of multiple actinic keratoses, with direct comparisons to topical agents and photodynamic therapy in cited studies.

Related treatments and guidelinesGuidelines and trials cited include comparisons of TCA versus photodynamic therapy and studies of phenol peels, 5‑fluorouracil combinations, and ALA‑PDT; J Am Acad Dermatol AK guideline (2021) and other systematic reviews are referenced.

15788	Chemical peel, facial, epidermal
15789	Chemical peel, facial, dermal
15792	Chemical peel, nonfacial, epidermal
15793	Chemical peel, nonfacial, dermal

D48.5	Neoplasm of uncertain behavior of skin
L57.0	Actinic keratosis
L70.0	Acne vulgaris
L70.1	Acne conglobata

OpenPayer

Chemical Peels (Dermatology)

Coverage Criteria

Coding

Provider Actions and Authorization

Background

Definitions